Subsys
NDC Package 71500-016-15

11-digit billing NDC: 71500001615 · Billing unit: EA · 30 EA per package

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Subsys is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.Patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg of oral morphine per day, at least 25 mcg of transdermal fentanyl per hour, at least 30 mg of oral oxycodone per day, at least 8 mg of oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60mg oral hydrocodone per day, or an equianalgesic dose of another opioid daily for a week or longer. Marketed by West Therapeutics Development, Llc, this product is identified by NDC 71500-016 and is authorized under FDA application NDA202788.

Identification & Billing

NDC Package Code
71500-016-15
Package Description
15 BLISTER PACK in 1 CARTON / 2 BOTTLE, SPRAY in 1 BLISTER PACK / 1 SPRAY in 1 BOTTLE, SPRAY
Product Code
11-Digit Billing Format
71500001615
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Subsys
Dosage Form
-
Usage Information
SUBSYS is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.Patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg of oral morphine per day, at least 25 mcg of transdermal fentanyl per hour, at least 30 mg of oral oxycodone per day, at least 8 mg of oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60mg oral hydrocodone per day, or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids when taking SUBSYS.Limitations of Use:Not for use in opioid non-tolerant patients.Not for use in the management of acute or postoperative pain, including headache/migraine, dental pain, or in the emergency room [see Contraindications ( 4)]. As part of the Transmucosal Immediate-Release Fentanyl (TIRF) REMS, SUBSYS may be dispensed by outpatient pharmacies only to outpatients enrolled in the program. [ see Warnings and Precautions ( 5.7)]. For inpatient administration of SUBSYS, patient and prescriber enrollment are not required.

Regulatory & Marketing

Labeler Name
West Therapeutics Development, Llc
FDA Application #
NDA202788
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-10-2021
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71500-016-15 identifies a specific commercial package of 15 blister pack in 1 carton / 2 bottle, spray in 1 blister pack / 1 spray in 1 bottle, spray of Subsys, labeled by West Therapeutics Development, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by West Therapeutics Development, Llc on March 10, 2021. The current certification is valid through December 31, 2022.

How is this West Therapeutics Development, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71500001615. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71500-016-15
11-Digit CMS (5-4-2)
71500-0016-15

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.